Abstract 230P
Background
As far as we know, we have yet to establish the long-term cancer outcomes of partial cystectomy (PC) for urothelial carcinoma. Radical cystectomy (RC) is a complex and risky procedure for muscle invasive bladder cancer (MIBC). In some cases, PC with bilateral pelvic lymph node dissection can be an option in selected patients but may compromise oncologic success. We compared the recurrence patterns and survival rates of patients who had either partial or radical cystectomy for MIBC patients with solitary tumor.
Methods
We identified 30 solitary MIBC patients with downgraded staging below cT2 after TURBT or neoadjuvant systemic therapy at our hospital from 2014 to 2021. They had either partial cystectomy or radical cystectomy and all of them had pathological T staging below pT2. We compare the overall survival, cancer specific survival and recurrence pattern including local recurrence and metastasis.
Results
The median postoperative follow-up period was 5 years, with a range of 1 to 8.5 years. When comparing patients who underwent partial cystectomy to those who underwent radical cystectomy, no significant differences were observed in the 5-year distant recurrence-free survival rates (100% vs 94.5%, p = 0.23) or cancer-specific survival rates (91.7% vs 100%, p = 0.43). Furthermore, there were no instances of extravesical pelvic tumor recurrence in either the partial or radical cystectomy groups postoperatively. Among the patients who underwent partial cystectomy, 6 out of 12 (50%) experienced intravesical recurrence of the tumor, and only 1 out of 12 (5.5%) ultimately required conversion to radical cystectomy.
Conclusions
For patients with solitary muscle-invasive bladder cancer that has been downgraded to a stage below cT2, partial cystectomy is a feasible option as it offers a similar metastasis-free survival and cancer-specific survival rate when compared to radical cystectomy. However, it is crucial to acknowledge that patients who received partial cystectomy remain at risk of experiencing recurrence within the bladder. Therefore, it is imperative to provide these patients with appropriate counseling and ongoing monitoring to address this potential risk.
Clinical trial identification
Not applicable
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
602P - COLUMBUS 7-year update: A randomized, open-label, phase III trial of encorafenib (Enco) + binimetinib (Bini) vs vemurafenib (Vemu) or Enco in patients (Pts) with BRAF V600-mutant melanoma
Presenter: Andrew Haydon
Session: Poster Display
Resources:
Abstract
603P - An individualised postoperative radiological surveillance schedule for IDH-wildtype glioblastoma patients (HK-GBM Registry)
Presenter: Jason Chak Yan Li
Session: Poster Display
Resources:
Abstract
604P - Cabozantinib versus placebo in patients with radioiodine-refractory differentiated thyroid cancer who progressed after prior VEGFR-targeted therapy: Outcomes from COSMIC-311 by BRAF status
Presenter: Marcia Brose
Session: Poster Display
Resources:
Abstract
606P - BRAF and NRAS mutations are associated with poor prognosis in Asians with acral-lentiginous and nodular cutaneous melanoma
Presenter: Sumadi Lukman Anwar
Session: Poster Display
Resources:
Abstract
607P - Single institutional outcomes of radiotherapy and systemic therapy for melanoma brain metastases in Japan
Presenter: Naoya Yamazaki
Session: Poster Display
Resources:
Abstract
608P - The efficacy of immune checkpoint inhibitors and targeted therapy in mucosal melanomas: A systematic review and meta-analysis
Presenter: Andrea Teo
Session: Poster Display
Resources:
Abstract
609P - The association between thyroid function abnormalities and vitiligo induced by pembrolizumab regarding prognosis in patients with advanced melanoma
Presenter: Moez Mobarek
Session: Poster Display
Resources:
Abstract
610P - Analyzing the clinical benefit of the evidence presented at these congresses and utilizing a standardized scale to quantify it will significantly enhance our understanding of the studies showcased, allowing for more objective evaluation and interpretation
Presenter: Charles Jeffrey Tan
Session: Poster Display
Resources:
Abstract
611P - ESMO-magnitude of clinical benefit scale (MCBS) scores for phase III trials of adjuvant and curative therapies at the 2022 ASCO annual meeting (ASCO22)
Presenter: Thi Thao Vi Luong
Session: Poster Display
Resources:
Abstract
612P - Is the juice worth the squeeze? Overall survival gain per unit treatment time as a metric of clinical benefit of systemic treatment in incurable cancers
Presenter: Vodathi Bamunuarachchi
Session: Poster Display
Resources:
Abstract